Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ILMN stock price vs NTRA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at NTRA's multiple
Needs NTRA P/E.
Implied fair value · at ILMN's multiple
Needs Annual EPS is negative, ILMN P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ILLUMINA, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
NATERA, INC. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
THERMO FISHER SCIENTIFIC INC.
ILMN vs TMO
AGILENT TECHNOLOGIES, INC.
ILMN vs A
DANAHER CORP /DE/
ILMN vs DHR
BIO-RAD LABORATORIES, INC.
ILMN vs BIO
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
ILMN vs PACB
EXACT SCIENCES CORP
ILMN vs EXAS
AMGEN INC
ILMN vs AMGN
VERTEX PHARMACEUTICALS INC / MA
ILMN vs VRTX
REGENERON PHARMACEUTICALS, INC.
ILMN vs REGN
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ILMN can re-accelerate growth without sacrificing its superior margins, then consider the name because it combines far better profitability and a much lower P/S multiple than NTRA; however, the case is weaker if you anchor strictly to DCF, which sits well below the current price.
ILMN trades at 6.9x P/S versus NTRA at 16.8x P/S, yet ILMN has stronger margins and profitability, which suggests the market is paying a large premium for NTRA’s growth. The implied price of $476.91 is 140.7% above ILMN’s current price of $198.16, but that comparison is anchored to NTRA multiple rather than ILMN’s own fundamentals.
Supporting Metrics
